Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price
The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs
The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
The campaign aims to promote an integrated view by combining Ayurveda and Yoga to create harmony not just within the body, but also in our minds
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
The integration and transition of the brands are expected to be completed by June 2022.
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Subscribe To Our Newsletter & Stay Updated
